<DOC>
	<DOCNO>NCT01818544</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability 28 day oral administration BAY85-8501 versus placebo subject non-CF Bronchiectasis ( BE ) . The secondary objective examine effect BAY85-8501 pulmonary function , biomarkers inflammation tissue damage , impact overall health perceive well-being evaluate pharmacokinetics BAY85-8501 .</brief_summary>
	<brief_title>Safety Efficacy Oral BAY85-8501 Patients With Non-CF ( Cystic Fibrosis ) Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Proven document diagnosis nonCF ( cystic fibrosis ) idiopathic postinfectious BE ( bronchiectasis ) compute tomography ( CT ) scan [ conventional high resolution CT consider standard ] , include 2 lobe dilate airway compatible BE initial diagnosis Stable pulmonary status indicate force , expire volume 1 second ( FEV1 ) percent predict ≥30 % &lt; 90 % ( postbronchodilator ) Stable ( i.e. , dose change ) regimen standard BE treatment administer least 4 week prior screen Cough day Forced , expire volume 1 second &lt; 30 % ≥90 % predict ( postbronchodilator ) Recent significant hemoptysis ( ≥300 mL require blood transfusion ) precede 4 week screen ( screen period ) Known cystic fibrosis and/or document chronic bronchial asthma Active allergic bronchopulmonary aspergillosis ( ABPA ) Diagnosis common variable immunodeficiency ( CVID ) Systemic inhale antibiotic treatment within 4 week prior screen Treatment exacerbation within 4 week prior screen Systemic corticosteroid &gt; 10 mg/day prednisolone equivalent &gt; 2 week within 4 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Elastase Inhibition</keyword>
</DOC>